Download PDF
Planta Med 2006; 72(7): 579-583
DOI: 10.1055/s-2006-931561
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Valerian Extract Ze 911 Inhibits Postsynaptic Potentials by Activation of Adenosine A1 Receptors in Rat Cortical Neurons

Z. Vissiennon1 , K. Sichardt1 , U. Koetter2 , A. Brattström2 , K. Nieber1
  • 1Institut für Pharmazie, Lehrstuhl Pharmakologie für Naturwissenschaftler, Universität Leipzig, Leipzig, Germany
  • 2Max Zeller Söhne AG, Herbal Medicinal Products, Romanshorn, Switzerland
Further Information

Publication History

Received: February 3, 2005

Accepted: January 16, 2006

Publication Date:
28 April 2006 (online)

    Permissions and Reprints

Corrected by:

Valerian Extract Ze 911 Inhibits Postsynaptic Potentials by Activation of Adenosine A1 Receptors in Rat Cortical NeuronsPlanta Med 2006; 72(08): 770-770
DOI: 10.1055/s-2006-947182

Abstract

In this study we evaluated the adenosine A1 receptor-mediated effect of valerian extract (Ze 911) on postsynaptic potentials (PSPs) in pyramidal cells of the rat cingulate cortex in a slice preparation. We first observed that N 6-cyclopentyladenosine (CPA, 0.01 - 10 μM), an adenosine A1 receptor agonist, inhibited PSPs in a concentration-dependent manner. The CPA (10 μM)-induced inhibition was antagonized by 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.1 μM), an adenosine A1 receptor antagonist. Ze 911 concentration dependently (0.1 - 15 mg/mL) inhibited PSPs in the presence of the adenosine A2A receptor antagonist 1,3,7-trimethyl-8-(3-chlorostyryl)xanthine (CSC, 0.2 μM) and adenosine deaminase (1 U/mL). The maximal inhibition induced by 10 mg/mL was completely antagonised by DPCPX (0.1 μM), an A1 receptor blocker. The data suggest that activation of adenosine A1 receptors is involved in the pharmacological effects of the valerian extract Ze 911.

Key words

Adenosine - adenosine A1 receptor - valerian - postsynaptic potential - pyramidal cells

References

  • 1 Huston J P, Haas H L, Boix F, Pfister M, Decking U, Schrader J. t al . Extracellular adenosine levels in neostriatum and hippocampus during rest and activity periods of rats.  Neuroscience. 1996;  73 99-107
    CrossrefPubMedGoogle Scholar
  • 2 Porkka-Heiskanen T, Strecker R E, McCarley R W. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study.  Neuroscience. 2000;  99 507-17
    CrossrefPubMedGoogle Scholar
  • 3 Fredholm B B, Abbracchio M P, Burnstock G, Daly J W, Jarden K T, Jacobson K A. et al . Nomenclature and classification of purinoceptors.  Pharmcol Rev. 1994;  46 143-56
    PubMedGoogle Scholar
  • 4 Palmer T M, Stiles G L. Neurotransmitter receptors. VII Adenosine receptors.  Neuropharmacology. 1995;  7 683-94
    PubMedGoogle Scholar
  • 5 Ralevic V, Burnstock G. Receptors for purines and pyrimidines.  Pharmacol Rev. 1998;  50 413-9
    PubMedGoogle Scholar
  • 6 Dixon A K, Guvitz A K, Sirinathsinghji D JS, Richardson P J, Freeman T C. Tissue distribution of adenosine receptor mRNAs in the rat.  Br J Pharmacol. 1996;  118 1461-8
    PubMedGoogle Scholar
  • 7 Benington J H, Kodali S K, Heller H C. Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation.  Brain Res. 1995;  692 79-85
    CrossrefPubMedGoogle Scholar
  • 8 Schwierin B, Borbely A A, Tobler I. Effects of N 6-cyclopentyladenosine and caffeine on sleep regulation in the rat.  Eur J Pharmacol. 1996;  107 653-63
    PubMedGoogle Scholar
  • 9 Marks G A, Shaffery J P, Speciale S G, Birabil C G. Enhancement of rapid eye movement sleep in the rat by actions at A1 and A2a adenosine receptor subtype with a differential sensitivity to atropine.  Neuroscience. 2003;  116 913-20
    CrossrefPubMedGoogle Scholar
  • 10 Blumenthal M. The 2002 top-selling herbal supplements in food, drug and mass market retail outlets.  Herbal Gram. 2003;  58 71
    PubMedGoogle Scholar
  • 11 Müller C E, Schumacher B, Brattström A, Abourashed E A, Koetter U. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors.  Life Sci. 2002;  71 1939-49
    CrossrefPubMedGoogle Scholar
  • 12 Müller C E. A1 adenosine receptors and their ligands: overview and recent developments.  Farmaco [Sci]. 2000;  56 77-80
    PubMedGoogle Scholar
  • 13 Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller C E. Ligands isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors.  J Nat Prod. 2002;  65 1479-85
    CrossrefPubMedGoogle Scholar
  • 14 Brand A, Vissiennon Z, Eschke D, Nieber K. Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons.  Neuropharmacology. 2001;  40 85-95
    PubMedGoogle Scholar
  • 15 Hentschel S, Lewerenz A, Nieber K. Activation of A3 receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons.  Restor Neurol Neurosci. 2003;  21 55-63
    PubMedGoogle Scholar
  • 16 Latini S, Bordoni F, Corradetti R, Pepeu G, Pedata F. Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices.  Br J Pharmacol. 1999;  128 1035-44
    CrossrefPubMedGoogle Scholar
  • 17 Leuschner J, Müller J, Rudmann M. Characterisation of the central nervous depressant activity of commercially available vaerian root extract.  Arzneimittelforschung. 1993;  43 638-41
    PubMedGoogle Scholar
  • 18 Lindahl O, Lindwall L. Double blind study of a valerian preparation.  Pharmacol Biochem Behav. 1989;  32 1065-6
    CrossrefPubMedGoogle Scholar
  • 19 Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on reaction time, alertness and concentration in volunteers.  Pharmacopsychiatry. 1999;  32 235-341
    PubMedGoogle Scholar
  • 20 Ziegler G, Ploch M, Miettinen-Baumann A, Coller W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia: a randomised, double-blind, comparative clinical study.  Eur J Med Res. 2002;  7 480-6
    PubMedGoogle Scholar
  • 21 Rodenbeck A, Simen S, Cohs S, Jordan W, Kinkelbur J, Staedt J. et al . Veränderte Schlafstruktur als Hinweis auf die GABAerge Wirkung eines Baldrian-Hopfen-Präparates bei Patienten mit psychophysiologischer Insomnie.  Somnologie. 1998;  2 26-31
    PubMedGoogle Scholar
  • 22 Füssel A, Wolf A, Brattström A. Effect of a fixed valerian-hop extract combination (Ze 91 119) on sleep polygraphy in patients with non-organic insomnia: a pilot study.  Eur J Med Res. 2000;  5 385-90
    PubMedGoogle Scholar
  • 23 Fredholm B B, Ijzerman A P, Jacobson K A, Klotz K N, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.  Pharmacol Rev. 2002;  53 527-52
    PubMedGoogle Scholar
  • 24 Cavadas C, Araujo I, Cotrim M D, Amaral T, Cunha A P, Macedo T. et al . In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain.  Arzneimittelforschung. 1995;  45 753-5
    PubMedGoogle Scholar
  • 25 Ortiz J G, Niebes-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3 H]flunitrazepam binding, synaptosomal [3 H]GABA uptake, and hippocampal GABA release.  Neurochem Res. 1999;  24 1373-8
    CrossrefPubMedGoogle Scholar
  • 26 Yuan C S, Mehendale S, Xiao Y, Aung H H, Xie J T, Ang-Lee M K. The gamma-aminobutyric acidergic effects of valerenic acid on rat brainstem neuronal activity.  Anesth Analg. 2004;  98 353-8
    PubMedGoogle Scholar
  • 27 Dietz B M, Mahady G B, Paul G F, Farnsworth N R. Valerenic acid are partial agonist of the 5-HT5a receptor in vitro .  Mol Brain Res. 2005;  138 91-7
    PubMedGoogle Scholar

Dr. Karen Nieber

Universität Leipzig

Institut für Pharmazie

Talstrasse 33

04103 Leipzig

Germany

Phone: +49-341-973-6812

Fax: +49-341-973-6898

Email: nieber@rz.uni-leipzig.de

      >